Artificial Intelligence Internship - 2026 Summer

Artificial Intelligence Internship - 2026 Summer

Los Angeles, CA

On-Site

Our Values

· Integrity

· Intelligence

· Initiative

What You Will Do

Writing and shipping production code in a tight loop: spec → AI implement → review → deploy, same day

Building and extending agents — the kind that run on a schedule, handle edge cases, and don't need babysitting

Owning features end-to-end, from requirements through deployment

Working directly with management in person

What We are Looking for

Real experience with autonomous agents or agentic frameworks

AI coding tools as your daily workflow — OpenClaw, Claude Code, Codex, Cursor, Windsurf

Full-stack enough to build the tooling and integrations agents need around them

SDD-fluent: specs tight enough for AI to implement, and you know how to review the output

Qualifications

Rising Senior - Undergraduate College Degree, or recent graduate

Masters Student between year 1 and two, or recent graduate

About Immix

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.